Chief Executive Officer

Chief Financial Officer

FORE Biotherapeutics Presents Phase 1/2a Plixorafenib Data Demonstrating Prolonged Duration of Effect in BRAF Altered Thyroid Cancers at American Thyroid Association® 2025 Annual Meeting

FORE Biotherapeutics to Participate in Upcoming Investor Conferences

Customer over capital: How Nebraska medtech startups beat the VC downturn

Despite top startup ranking, Philly VC funding hits five-year low

Scientific Director

Fore Biotherapeutics is a next-generation precision oncology company focused on developing plixorafenib, an investigational small-molecule inhibitor of mutated BRAF. The Scientific Director will play a cross-functional role supporting clinical development programs, contributing to the design, data collection, and reporting of clinical studies while mentoring junior scientists.

Sign up with Google

Sign in with Google